Implant Pouch Creates Vascularized Tissue Pocket
By HospiMedica International staff writers Posted on 16 Sep 2014 |
Image: The CorMatrix CanGaroo ECM envelope (Photo courtesy of CorMatrix).
A new envelope made from extracellular matrix (ECM) creates a stable environment for cardiac implantable electronic devices (CIEDs).
The CorMatrix CanGaroo ECM envelope is constructed from a multi-laminate sheet of decellularized, non-crosslinked, lyophilized ECM derived from porcine small intestinal submucosa, which serves as a bioscaffold for vascular ingrowth from adjacent tissues delivering progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM material is naturally degraded and resorbed, gradually replaced by the patient’s own cells, leaving remodeled functional tissue where damaged or injured tissue would normally be expected.
The ECM envelope, which is provided in four different sizes, is intended to hold an array of device types and sizes, such as pacemakers, cardiac resynchronization therapy (CRT) devices, or implantable cardioverter defibrillators (ICDs), after the surgical procedure has been completed. The CorMatrix CanGaroo ECM Envelope is a product of CorMatrix (Rosewell, GA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“The CorMatrix CanGaroo was designed to address the needs described to us by physicians implanting CIED’s in their daily practice,” said John Davis, executive vice president of sales and marketing at CorMatrix. “We are pleased that we can provide a device that our physician’s requested to address complications with CIED implantation.”
Related Links:
CorMatrix
The CorMatrix CanGaroo ECM envelope is constructed from a multi-laminate sheet of decellularized, non-crosslinked, lyophilized ECM derived from porcine small intestinal submucosa, which serves as a bioscaffold for vascular ingrowth from adjacent tissues delivering progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM material is naturally degraded and resorbed, gradually replaced by the patient’s own cells, leaving remodeled functional tissue where damaged or injured tissue would normally be expected.
The ECM envelope, which is provided in four different sizes, is intended to hold an array of device types and sizes, such as pacemakers, cardiac resynchronization therapy (CRT) devices, or implantable cardioverter defibrillators (ICDs), after the surgical procedure has been completed. The CorMatrix CanGaroo ECM Envelope is a product of CorMatrix (Rosewell, GA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“The CorMatrix CanGaroo was designed to address the needs described to us by physicians implanting CIED’s in their daily practice,” said John Davis, executive vice president of sales and marketing at CorMatrix. “We are pleased that we can provide a device that our physician’s requested to address complications with CIED implantation.”
Related Links:
CorMatrix
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure